An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease

Trial Profile

An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs SHP 610 (Primary)
  • Indications Mucopolysaccharidosis III
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CHIL4317
  • Sponsors Shire
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 Apr 2017 Planned number of patients changed from 21 to 17.
    • 01 Nov 2016 Status changed from recruiting to discontinued, as per Shire media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top